Cargando…

High‐sensitive clinical diagnostic method for PTPRZ1‐MET and the characteristic protein structure contributing to ligand‐independent MET activation

BACKGROUND: PTPRZ1‐MET (ZM) is a critical genetic alteration driving the progression of lower‐grade glioma. Glioma patients harboring ZM could benefit from MET inhibitors. According to the remarkable role of ZM as a driver of glioma progression and indicator of MET inhibitor sensitivity, it is neces...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Ruoyu, Liu, Yanwei, Wang, Kuanyu, Wang, Zheng, Zhang, Chuanbao, Zhang, Wei, Zhao, Zheng, Li, Guanzhang, Huang, Lijie, Chang, Yuanhao, Zeng, Fan, Jiang, Tao, Hu, Huimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025647/ https://www.ncbi.nlm.nih.gov/pubmed/33645009 http://dx.doi.org/10.1111/cns.13627

Ejemplares similares

Recurrent PTPRZ1‐MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases
por: Chai, Rui‐Chao, et al.
Publicado: (2021)

Tumour exosomes from cells harbouring PTPRZ1–MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma
por: Zeng, A-L, et al.
Publicado: (2017)

Receptor tyrosine kinase expression in high-grade gliomas before and after chemoradiotherapy
por: Wang, Kuanyu, et al.
Publicado: (2019)

RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas
por: Bao, Zhao-Shi, et al.
Publicado: (2014)

RGS16 promotes glioma progression and serves as a prognostic factor
por: Huang, Ruoyu, et al.
Publicado: (2020)

CKAP2 expression is associated with glioma tumor growth and acts as a prognostic factor in high-grade glioma
por: Wang, Kuanyu, et al.
Publicado: (2018)

Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme
por: Chen, Bao-Shi, et al.
Publicado: (2020)

EFEMP2 indicates assembly of M0 macrophage and more malignant phenotypes of glioma
por: Huang, Lijie, et al.
Publicado: (2020)

Comprehensive Analysis of the Clinical and Biological Significances of Endoplasmic Reticulum Stress in Diffuse Gliomas
por: Huang, Ruoyu, et al.
Publicado: (2021)

Corrigendum: Comprehensive analysis of the clinical and biological significances of endoplasmic reticulum stress in diffuse gliomas
por: Huang, Ruoyu, et al.
Publicado: (2022)

Identification of an ATP metabolism‐related signature associated with prognosis and immune microenvironment in gliomas
por: Huang, Ruoyu, et al.
Publicado: (2020)

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
por: Martin, Valentina, et al.
Publicado: (2019)

FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide
por: Zhou, Kaijia, et al.
Publicado: (2021)

RELB: A novel prognostic marker for glioblastoma as identified by population-based analysis
por: Zeng, Fan, et al.
Publicado: (2019)

ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity
por: Zhou, Kaijia, et al.
Publicado: (2020)

ADAR3 expression is an independent prognostic factor in lower-grade diffuse gliomas and positively correlated with the editing level of GRIA2(Q607R)
por: Zhang, Ying, et al.
Publicado: (2018)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
por: Sun, Dantong, et al.
Publicado: (2023)

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2021)

Multidimensional analysis of gene expression reveals TGFB1I1-induced EMT contributes to malignant progression of astrocytomas
por: Liu, Yanwei, et al.
Publicado: (2014)

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
por: Kou, Jianqun, et al.
Publicado: (2018)

Decorin is a novel antagonistic ligand of the Met receptor
por: Goldoni, Silvia, et al.
Publicado: (2009)

Redox Regulator GLRX Is Associated With Tumor Immunity in Glioma
por: Chang, Yuanhao, et al.
Publicado: (2020)

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
por: Liao, Haiyan, et al.
Publicado: (2021)

HGF-independent Potentiation of EGFR Action by c-Met
por: Dulak, Austin M., et al.
Publicado: (2011)

Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma
por: Wu, Fan, et al.
Publicado: (2018)

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
por: Peng, Lun-Xi, et al.
Publicado: (2021)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts
por: Ji, Fujian, et al.
Publicado: (2015)

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
por: Jie, Guang-Ling, et al.
Publicado: (2023)

The AKT-independent MET–V-ATPase–MTOR axis suppresses liver cancer vaccination
por: Huang, Xing, et al.
Publicado: (2020)

Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
por: Wang, Zheng, et al.
Publicado: (2016)

Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
por: Sun, Boyang, et al.
Publicado: (2023)

MET mutation causes muscular dysplasia and arthrogryposis
por: Zhou, Hang, et al.
Publicado: (2019)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
por: Huang, Lei, et al.
Publicado: (2020)

Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
por: Li, Pengyun, et al.
Publicado: (2023)

Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer
por: Lv, Huilai, et al.
Publicado: (2015)

Met carriers of the BDNF Val66Met polymorphism show reduced Glx/NAA in the pregenual ACC in two independent cohorts
por: Martens, Louise, et al.
Publicado: (2021)

Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts
por: LIU, KAI, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lsn849gj31ejgmua4dgnkvt6ng